Flexion Therapeutics (NASDAQ:FLXN) shares traded 1.44% up during most recent session to reach at the closing price of $25.37. The stock exchanged hands 1.88 Million shares versus average trading capacity of 1.04 Million shares, yielding a market cap of $816.66 Million. Wall Street analysts covering the stock are projecting that the stock will reach $39.5 within the next 52-weeks. The mean target projections are based on 8 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Flexion Therapeutics (NASDAQ:FLXN) high price target of $44 and with a conservative view have low price target of $37.
BMO Capital “Maintained” Flexion Therapeutics (NASDAQ:FLXN) in a research note issued to investors on 10/09/17 to Outperform with price target of $37.
Additionally on 8/24/17 Northland Securities “Initiates Coverage On” Flexion Therapeutics (NASDAQ:FLXN) to Outperform setting price target at $40 and on 12/22/16 Raymond James “Initiates Coverage On” the stock to Strong Buy at $0. Furthermore on 9/06/16 Lake Street “Assumes” the stock to Buy at $38.
On the other hand the company has Relative Strength Index (RSI 14) of 50 along with Average True Range (ATR 14) of 1.61, Consequently Flexion Therapeutics (NASDAQ:FLXN)’s weekly and monthly volatility is 4.95%, 6.50% respectively. The company’s beta value is at 1.12.
In terms of Buy, Sell or Hold recommendations, Flexion Therapeutics (NASDAQ:FLXN) has analysts’ mean recommendation of 1.7. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Flexion Therapeutics (NASDAQ:FLXN)’s minimum EPS for the current quarter is at $-1.32 and can go high up to $-0.67. The consensus mean EPS for the current quarter is at $-0.95 derived from a total of 8 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.65 earnings per share for the same quarter during last year.
Previously Flexion Therapeutics (NASDAQ:FLXN) reported $-0.91 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.82 by $-0.09. The company posted an earnings surprise of -11%.
Currently Flexion Therapeutics (NASDAQ:FLXN)’s shares owned by insiders are 0.3%, whereas shares owned by institutional owners are 0%. However the six-month change in the insider ownership was recorded 5.6%, as well as three-month change in the institutional ownership was recorded -0.03%.
Flexion Therapeutics (NASDAQ:FLXN) 52-week high price stands at $32.25 and low price stands at $15.93, its price distance from 52-week high is -21.33% while its distance from 52-week low price is 59.26%. The stock hit its 52-week high on 10/06/17, and 52-week low on 11/08/16.
Flexion Therapeutics (NASDAQ:FLXN)’s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0. Its book value per share for the most recent quarter is $6.39 while its price to book ratio for the same period is 3.97, as for as the company’s cash per share for the most recent quarter is $11.18, however its price to cash per share ratio for the same period is 2.27. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.